Pharmaceutical Services

Parallel Import Licences

Home Page / Responsibilities / Regulatory / Post-approval procedures / Notifications to Marketing Authorisations / Parallel Import Licences

    The patient information leaflet of the parallel imported medicinal product must always be in accordance with that of the reference product. The holder of a parallel import licence must therefore monitor any changes to the reference product. If any changes occur he must submit a notification to the Medicines Council for the update of patient information leaflet in order for it to comply with the most recently approved information of the reference product.



Back to previous page

Share